---
title: "Xtandi (enzalutamide) in castration-resistant prostate cancer: Indication questions"
description: "Indication questions on Xtandi (enzalutamide) in castration-resistant prostate cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Is Xtandi approved for castration-resistant prostate cancer (CRPC)? Xtandi indication: what is castration-resistant prostate cancer (CRPC)? 2 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xtandi (enzalutamide) in castration-resistant prostate cancer: Indication questions

Manufacturer: Astellas Pharma US, Inc.; Pfizer Inc.  
Prescribing information: [Xtandi](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf)

Indication questions that apply to every indication of Xtandi are on [Xtandi (enzalutamide), all indications: Indication](https://www.evicenter.com/medical-information/xtandi/indication).

## Indication

<a id="xtandi-crpc-indication"></a>

### Is Xtandi approved for castration-resistant prostate cancer (CRPC)?

> “XTANDI<sup>®</sup> is indicated for the treatment of patients with: 
> • 
> castration-resistant prostate cancer (CRPC)”

Source: [XTANDI: Prescribing information, page 2, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=2)

<a id="xtandi-crpc-definition"></a>

### Xtandi indication: what is castration-resistant prostate cancer (CRPC)?

> “CRPC is defined as disease progression on androgen deprivation therapy despite castrate levels of testosterone.<sup>17</sup>”

Source: [XTANDI: XTANDI® (enzalutamide), captured 2026-11-13](https://www.xtandihcp.com/about-xtandi/milestones#:~:text=CRPC%20is%20defined%20as%20disease,therapy%20despite%20castrate%20levels%20of)

> “CRPC can be nonmetastatic (no radiographic evidence of metastasis) or metastatic (evidence of metastatic disease).<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Understanding nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/about#:~:text=CRPC%20can%20be%20nonmetastatic%20%28no,or%20metastatic%20%28evidence%20of%20metastatic)

## Related pages
- [Medical information: Xtandi (enzalutamide): Castration-resistant prostate cancer](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer)
- [Clinical trials](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/guidelines)
